SI1530636T1 - Zdravljenje melanoma z zniĹľanjem nivojev klusterina - Google Patents

Zdravljenje melanoma z zniĹľanjem nivojev klusterina

Info

Publication number
SI1530636T1
SI1530636T1 SI200331891T SI200331891T SI1530636T1 SI 1530636 T1 SI1530636 T1 SI 1530636T1 SI 200331891 T SI200331891 T SI 200331891T SI 200331891 T SI200331891 T SI 200331891T SI 1530636 T1 SI1530636 T1 SI 1530636T1
Authority
SI
Slovenia
Prior art keywords
clusterin
melanoma
subject
bcl
reduction
Prior art date
Application number
SI200331891T
Other languages
English (en)
Inventor
Burkhard Jansen
Martin E Gleave
Original Assignee
Stry Liaison Ofiice The University Of British Columbia Umiversity Indu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stry Liaison Ofiice The University Of British Columbia Umiversity Indu filed Critical Stry Liaison Ofiice The University Of British Columbia Umiversity Indu
Publication of SI1530636T1 publication Critical patent/SI1530636T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
SI200331891T 2002-08-21 2003-08-21 Zdravljenje melanoma z zniĹľanjem nivojev klusterina SI1530636T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US31974802P 2002-12-02 2002-12-02
US47238703P 2003-05-20 2003-05-20
EP03792074A EP1530636B1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels
PCT/CA2003/001276 WO2004018675A1 (en) 2002-08-21 2003-08-21 Treatment of melanoma by reduction in clusterin levels

Publications (1)

Publication Number Publication Date
SI1530636T1 true SI1530636T1 (sl) 2010-12-31

Family

ID=31950766

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331891T SI1530636T1 (sl) 2002-08-21 2003-08-21 Zdravljenje melanoma z zniĹľanjem nivojev klusterina

Country Status (16)

Country Link
US (1) US7285541B2 (sl)
EP (1) EP1530636B1 (sl)
JP (1) JP4620585B2 (sl)
KR (1) KR101052289B1 (sl)
AT (1) ATE478142T1 (sl)
AU (1) AU2003258425B2 (sl)
CA (1) CA2494764C (sl)
CY (1) CY1110936T1 (sl)
DE (1) DE60333839D1 (sl)
DK (1) DK1530636T3 (sl)
IL (1) IL166657A (sl)
NO (1) NO333254B1 (sl)
NZ (1) NZ538288A (sl)
PT (1) PT1530636E (sl)
SI (1) SI1530636T1 (sl)
WO (1) WO2004018675A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
DE60322509D1 (de) 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
CA2882443C (en) 2002-08-21 2016-12-13 The University Of British Columbia Rnai probes targeting cancer-related proteins
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2007530453A (ja) * 2004-03-19 2007-11-01 ザ　ペン　ステート　リサーチ　ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
EP2190870A4 (en) * 2007-08-28 2010-12-01 Auckland Uniservices Ltd CELL MARKER OF MELANOCYTIC CELL LINE AND USE THEREOF
ES2734886T3 (es) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
MX2013010524A (es) 2011-03-15 2013-12-06 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
CN103906838A (zh) 2011-10-25 2014-07-02 Isis制药公司 Gccr表达的反义调节
CN104159611A (zh) 2012-02-22 2014-11-19 阿莱斯亚生物疗法股份有限公司 共使用簇集蛋白抑制剂和egfr抑制剂以治疗癌症
WO2014138338A1 (en) 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
WO2014159775A1 (en) * 2013-03-14 2014-10-02 Teva Pharmaceutical Industries Ltd. Anti-clusterin monotherapy for cancer treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100820266B1 (ko) * 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
EP1242050A4 (en) 1999-12-21 2004-05-26 Univ Yale STIMULATION OF ANGIOGEN SE BY THE USE OF SURVIVIN
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
DE60322509D1 (de) 2002-01-17 2008-09-11 Univ British Columbia Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
CA2882443C (en) 2002-08-21 2016-12-13 The University Of British Columbia Rnai probes targeting cancer-related proteins
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8061408B2 (en) 2009-10-13 2011-11-22 Varel Europe S.A.S. Casting method for matrix drill bits and reamers

Also Published As

Publication number Publication date
KR20050058425A (ko) 2005-06-16
NO20051426L (no) 2005-05-12
CA2494764C (en) 2013-04-23
AU2003258425A1 (en) 2004-03-11
IL166657A (en) 2010-05-31
NZ538288A (en) 2008-04-30
DE60333839D1 (de) 2010-09-30
US7285541B2 (en) 2007-10-23
CA2494764A1 (en) 2004-03-04
JP4620585B2 (ja) 2011-01-26
DK1530636T3 (da) 2010-11-29
ATE478142T1 (de) 2010-09-15
PT1530636E (pt) 2010-11-17
EP1530636B1 (en) 2010-08-18
CY1110936T1 (el) 2015-06-10
EP1530636A1 (en) 2005-05-18
KR101052289B1 (ko) 2011-07-27
AU2003258425B2 (en) 2008-02-14
NO333254B1 (no) 2013-04-22
JP2006502243A (ja) 2006-01-19
WO2004018675A1 (en) 2004-03-04
IL166657A0 (en) 2006-01-15
US20040082534A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
NO20051426L (no) Behandling av melanom ved reduksjon i clusterin-nivaer
WO2000049937A3 (en) Trpm-2 antisense therapy
WO2007085018A3 (en) Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
WO2001074376A3 (en) Cathepsin inhibitors in cancer treatment
WO2007079203A3 (en) Treatment for cutaneous t cell lymphoma
UA89226C2 (en) Imidazole compounds
MXPA05012619A (es) Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
ATE353010T1 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
IL156827A0 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
TW200504210A (en) A nucleolin antisense inhibiting growth of cancer cell
EP1218395A4 (en) ANTISENSE MODULATION OF X-CONNECTED INHIBITORS OF APOPTOSIS EXPRESSION
TW200515914A (en) Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
AU3934000A (en) Inhibitors of endothelin-1 synthesis
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
Lee et al. Radix clematidis extract inhibits UVB-induced MMP expression by suppressing the NF-κB pathway in human dermal fibroblasts
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SI1003554T1 (sl) Inhibitor protonske črpalke v terapevtski kombinaciji z antibakterijskimi snovmi
WO2003062197A3 (en) Nek2 inhibitors
WO2003105754A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION
WO2001074381A3 (en) Calpain inhibitors in cancer treatment
RS95204A (en) Combination for the treatment of airway disorders
WO2003072031A3 (en) Treatment of disease by inducing cell apoptosis